Source:http://linkedlifedata.com/resource/pubmed/id/10433077
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1999-8-12
|
pubmed:abstractText |
We previously reported that a decreased TCR mediated activity of the GTP-GDP binding p21ras protooncogene is associated with prediabetes in non-obese diabetic (NOD) mice. Furthermore, prevention of autoimmune diabetes is associated with reversal of the p21ras signaling defect in NOD T cells. Based on these animal studies we determined the activation of p21ras in PBMC from patients with Insulin Dependent Diabetes Mellitus (IDDM), Non-Insulin Dependent Diabetes Mellitus (NIDDM) and normal healthy controls. Stimulation by PHA induced a decrease of 3.7 +/- 1.4% and an increase of 2.44 +/- 2.3%, p < 0.02 and 2.6 +/- 1.6%,p < 0.003 in the basal unstimulated p21ras activity in the IDDM, NIDDM and normal control groups, respectively. Expression of p21ras and its regulatory elements, the GTPase activating protein p120ras-GAP and the guanine nucleotide releasing factor (GNRF) hSOS, was comparable in the three groups. The in vitro proliferative response to PHA was comparable in the IDDM and control groups: stimulation index (SI) of 8.6 +/- 2.5 and 9.4 +/- 3.5 respectively, p < 0.44. No correlations were found in the IDDM patients between the degree of p21ras activation and the mitogen induced in vitro proliferative response or the various clinical parameters including age, gender, disease duration, daily insulin requirements and metabolic control. Taken together these data indicate that PBMC from IDDM patients are characterized by a persistent impairment in the activation of their p21ras. They also suggest that p21ras stimulated activity is a sensitive and independent parameter of PBMC activation in these patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0891-6934
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
147-54
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10433077-Adolescent,
pubmed-meshheading:10433077-Adult,
pubmed-meshheading:10433077-Aged,
pubmed-meshheading:10433077-Child,
pubmed-meshheading:10433077-Child, Preschool,
pubmed-meshheading:10433077-Diabetes Mellitus, Type 1,
pubmed-meshheading:10433077-Female,
pubmed-meshheading:10433077-Genes, ras,
pubmed-meshheading:10433077-Humans,
pubmed-meshheading:10433077-Leukocytes, Mononuclear,
pubmed-meshheading:10433077-Lymphocyte Activation,
pubmed-meshheading:10433077-Male,
pubmed-meshheading:10433077-Middle Aged,
pubmed-meshheading:10433077-Proto-Oncogene Proteins p21(ras)
|
pubmed:year |
1999
|
pubmed:articleTitle |
Defective activation of p21ras in peripheral blood mononuclear cells from patients with insulin dependent diabetes mellitus.
|
pubmed:affiliation |
Diabetes Unit, Assaf Harofeh Medical Center, Zerifin, Israel.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|